Posts by Appnet

2 months ago

SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer

King of Prussia, PA – June 9, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of…

Press Releases

3 months ago

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected mid-2025 Dual PROTAC strategy overcomes hook effect and…

Press Releases

4 months ago

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago

Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by…

Press Releases

7 months ago

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

King of Prussia, PA – January 28, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein…

Press Releases

10 months ago

Nature: Protein degraders push into novel target space

Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory. Learn More

Press Releases

11 months ago

SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors

Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in Eisai’s Oncology Business Group Brings Nearly…

Press Releases

1 year ago

SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai

The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to…

Press Releases

1 year ago

SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology

March 6, 2024: Nature Biotechnology, a transformative journal covering the science and business of biotechnology, published a review article on the significant challenges facing…

Press Releases

2 years ago

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a biotech company focused on harnessing and engineering Molecular Glues for targeted protein degradation…

Press Releases

2 years ago

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law Schools, Brings Five Decades of Experience in Global Health, Law, Governance, and International Business

NEW YORK, October 23, 2023 – SEED Therapeutics (SEED), an innovative global biotech company focused on engineering “molecular glues” and harnessing its targeted protein degradation (TPD) platform…

Press Releases

2 years ago

Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

New York, NY – June 20, 2023 – SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary and global research company focused on harnessing and engineering “molecular glues,”…

News

3 years ago

Transforming Undruggable Targets into Tempotherapeutics

Forward-looking Statements This presentation contains forward-looking statements about SEED Therapeutics, Inc., and/or its Affiliates. Forward-looking statements are based on management’s beliefs and assumptions and…

Press Releases

3 years ago

Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania.

King of Prussia, PA – July 01, 2022 – Seed Therapeutics has completed construction of a state of the art 10,000 square foot innovation and…

Press Releases

5 years ago

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines. NEW YORK – November 13, 2020 – Seed Therapeutics (“the…

Press Releases

5 years ago

BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform

“Molecular Glue” Protein Degradation Serves as Alternative Approach to Cancer Treatment NEW YORK – August 7, 2020 – Seed Therapeutics Inc. (the “Company” or…